• Corpus ID: 46905394

Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria : a multi-centre , double-blind , random-ized , placebo-controlled study

  title={Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria : a multi-centre , double-blind , random-ized , placebo-controlled study},
  author={Torsten Zuberbier and Alexandru Oanță and Ewa Bogacka and Iris Medina and Frederiek Wesel and P. Uhl and Ignacio Ant{\'e}para and Ignacio J{\'a}uregui and Rom{\'a}n Valiente},
Department of Dermatology and Allergy, Charité Universitätsmedizin Berlin, Germany; S. C. Dermamed SRL, Brasov, Romania; NZOZ Materia Medica, Wroclaw, Poland; Centro Médico Vitae, Buenos Aires, Argentina; Cabinet d’Allergologie, Nantes, France; Arzt für Haut-u. Geschlechlskrankheiten Allergologie, Berlin, Germany; Hospital de Basurto, Servicio de Alergologia, Bilbao, Spain; FAES FARMA, S.A., Bilbao, Spain 

Figures and Tables from this paper

Effect of antihistamine up-dosing in chronic urticaria.

Considering the high safety profile of these drugs, it would be a good option to evaluate their efficacy at high doses, before moving on to other therapeutic steps.

Bilastine and quality of life.

Throughout its clinical development, bilastine has been shown to be more effective than placebo and at least as effective as cetirizine, levocetirIZine, fexofenadine or desloratadine in controlling the symptoms of seasonal allergic rhinitis and chronic urticaria.



Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double‐blind, parallel‐group study

  • P. KunaC. Bachert R. Valiente
  • Medicine
    Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
  • 2009
Background Bilastine is a new non‐sedative H1 receptor antagonist, indicated for the treatment of allergic rhinitis (AR) (seasonal and perennial).

Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled, parallel, multicenter study

Levocetirizine is an antihistamine from the latest generation approved for CIU, which impedes significantly a patient's quality of life (QoL).

Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial.

Compared with placebo, desloratadine significantly improved the total CIU symptom score as well as pruritus, the number of hives, and the size of the largest hive; overall therapeutic response and global CIU status improved significantly with deslor atadine.

Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study.

Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled study

This paper focuses on the treatment of chronic urticaria, a common skin condition that is frequently a disabling disease because of the persistence of clinical symptoms, the unpredictable course and its negative influence on the quality of life.

Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.

  • H. NelsonR. ReynoldsJ. Mason
  • Medicine, Psychology
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2000

Efficacy and Safety of Desloratadine in Adults with Chronic Idiopathic Urticaria

Once-daily desloratadine 5mg is well tolerated and superior to placebo in reducing pruritus and wheals associated with CIU.

Comparison of Peripheral and Central Effects of Single and Repeated Oral Dose Administrations of Bilastine, a New H1 Antihistamine: A Dose-Range Study in Healthy Volunteers With Hydroxyzine and Placebo as Control Treatments

A clear dissociation between peripheral anti-H1 and central nervous system activity was found after BIL treatment and significant and sustained peripheral H1-blocking effects were observed after both single and repeated administrations of the therapeutic dose of 20 mg BIL.

Review of H1 antihistamines in the treatment of chronic idiopathic urticaria.

The literature was reviewed to compare the currently available oral H1 antihistamines regarding their efficacy and safety at a wide range of doses and if sedation and cognitive impairment are considered relevant to treatment selection due to their effect on QOL and safety, then newer-generation agents should be selected over older-generation antihistamine.